In the highly regulated world of biopharmaceutical manufacturing, residual contaminants – like host cell DNA, plasmid fragments, mycoplasma and process enzymes – pose critical risks to product safety, efficacy, and regulatory compliance. Undetected impurities can trigger costly batch failures, delayed timelines, and patient safety concerns.